ClinicalTrials.gg

TargetBeta

CFB

complement factor B · also H2-Bf, BFD, BF · Serine proteases

8 programs in company-led studies act on CFB, from 7 companies: 5 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
iptacopanruleNovartisphase 32512 running–ChEMBL
NTQ5082ruleSino Biopharmaceuticalphase 366 running–the studies' text
FXS6837Fosun Pharmaphase 344 running–the company's pipeline
HRS-5965Jiangsu HengRui Medicinephase 3143 running–the company's pipeline
sefaxersenHoffmann-La Rochephase 311 running–a judged reading
HS-10542Hansoh Pharmaceutical Groupphase 233 running–the company's pipeline
FWY003Novartisphase 211 running–the company's pipeline
SAR446597Sanofiphase 211 runningC1Sthe company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.